Literature DB >> 29330216

Is placebo response in antidepressant trials rising or not? A reanalysis of datasets to conclude this long-lasting controversy.

Toshi A Furukawa1, Andrea Cipriani2,3, Stefan Leucht4, Lauren Z Atkinson2,3, Yusuke Ogawa1, Nozomi Takeshima1, Yu Hayasaka1, Anna Chaimani5,6,7, Georgia Salanti8.   

Abstract

It had long been believed that placebo response rates in antidepressant trials have been increasing and that they were responsible for rising numbers of so-called failed antidepressant trials. Two recent systematic reviews examined this issue and reached completely opposite findings. Furukawa and colleagues in a paper published in 2016 found that the placebo response rates are stable since 1991 and the apparent increase up to 2000 was confounded by changes in trial design features. By contrast, Khan and colleagues more recently concluded that placebo response rates had grown steadily in the past 30 years. The two reviews differed in the datasets they used, definitions of placebo response and statistical analyses. In this perspective article, we examined if such differences were responsible for the two reviews' contrasting conclusions. Our reanalyses confirmed our previous results. We found that in any dataset and for any placebo response definition, there was no increase in placebo response over the years when the analysis was adjusted for the confounders related to study design features or when it was limited to studies published after 1990s. We conclude that placebo response in antidepressant trials has remained stable for the past 25 years, during which time the large majority of the studies have come to share similar design features. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Keywords:  depression & mood disorders

Mesh:

Substances:

Year:  2018        PMID: 29330216     DOI: 10.1136/eb-2017-102827

Source DB:  PubMed          Journal:  Evid Based Ment Health        ISSN: 1362-0347


  12 in total

1.  Power behind the throne: A clinical trial simulation study evaluating the impact of controllable design factors on the power of antidepressant trials.

Authors:  Astrid Chevance; Florian Naudet; Raphaël Gaillard; Philippe Ravaud; Raphaël Porcher
Journal:  Int J Methods Psychiatr Res       Date:  2019-04-17       Impact factor: 4.035

2.  Raising Placebo Efficacy in Antidepressant Trials Across Decades Explained by Small-Study Effects: A Meta-Reanalysis.

Authors:  Lisa Holper
Journal:  Front Psychiatry       Date:  2020-07-28       Impact factor: 4.157

Review 3.  A systematic review and combined meta-analysis of concentration of oral amisulpride.

Authors:  Lin Li; Lu Li; De-Wei Shang; Yu-Guan Wen; Yu-Ping Ning
Journal:  Br J Clin Pharmacol       Date:  2020-03-03       Impact factor: 4.335

4.  Impact of placebo arms on outcomes in antidepressant trials: systematic review and meta-regression analysis.

Authors:  Georgia Salanti; Anna Chaimani; Toshi A Furukawa; Julian P T Higgins; Yusuke Ogawa; Andrea Cipriani; Matthias Egger
Journal:  Int J Epidemiol       Date:  2018-10-01       Impact factor: 7.196

5.  Guidelines for the pharmacological acute treatment of major depression: conflicts with current evidence as demonstrated with the German S3-guidelines.

Authors:  Martin Plöderl; Michael P Hengartner
Journal:  BMC Psychiatry       Date:  2019-09-02       Impact factor: 3.630

6.  Evidence synthesis, practice guidelines and real-world prescriptions of new generation antidepressants in the treatment of depression: a protocol for cumulative network meta-analyses and meta-epidemiological study.

Authors:  Yan Luo; Anna Chaimani; Yuki Kataoka; Edoardo Giuseppe Ostinelli; Yusuke Ogawa; Andrea Cipriani; Georgia Salanti; Toshi A Furukawa
Journal:  BMJ Open       Date:  2018-12-09       Impact factor: 2.692

7.  Visualizing the evolution of evidence: Cumulative network meta-analyses of new generation antidepressants in the last 40 years.

Authors:  Yan Luo; Anna Chaimani; Toshi A Furukawa; Yuki Kataoka; Yusuke Ogawa; Andrea Cipriani; Georgia Salanti
Journal:  Res Synth Methods       Date:  2020-05-25       Impact factor: 5.273

Review 8.  Neuropathic pain clinical trials: factors associated with decreases in estimated drug efficacy.

Authors:  Nanna B Finnerup; Simon Haroutounian; Ralf Baron; Robert H Dworkin; Ian Gilron; Maija Haanpaa; Troels S Jensen; Peter R Kamerman; Ewan McNicol; Andrew Moore; Srinivasa N Raja; Niels T Andersen; Emily S Sena; Blair H Smith; Andrew S C Rice; Nadine Attal
Journal:  Pain       Date:  2018-11       Impact factor: 7.926

9.  Comparative efficacy of placebos in short-term antidepressant trials for major depression: a secondary meta-analysis of placebo-controlled trials.

Authors:  Lisa Holper; Michael P Hengartner
Journal:  BMC Psychiatry       Date:  2020-09-07       Impact factor: 3.630

Review 10.  Placebo Responses and Placebo Effects in Functional Gastrointestinal Disorders.

Authors:  Paul Enck; Sibylle Klosterhalfen
Journal:  Front Psychiatry       Date:  2020-08-25       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.